The Role and Impact of Minimal Residual Disease in NSCLC.
Adjuvant therapy
Lung cancer
Minimal residual disease
NSCLC
ctDNA
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
04 11 2021
04 11 2021
Historique:
accepted:
25
04
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
19
2
2022
Statut:
epublish
Résumé
There has been a huge development in the assessment of malignancies through liquid biopsies last years, especially for NSCLC, where its use has become part of clinical practice in some settings. We aim to summarize current evidence about minimal residual disease and its use in lung cancer. Recent studies using ctDNA in NSCLC but also in other types of cancer found strong correlations between the presence of ctDNA and the risk of disease progression or death after curative intent, despite current technical difficulties in performing this analysis (high sensitivity and specificity required). Evaluation of MRD in NSCLC, especially through ctDNA, could be an important point in future trial designs and could permit a more "targeted" adjuvant treatment.
Identifiants
pubmed: 34735646
doi: 10.1007/s11912-021-01131-w
pii: 10.1007/s11912-021-01131-w
pmc: PMC8568856
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Informations de copyright
© 2021. The Author(s).